| Patient name: | Anna |
| Age: | 56 |
| Height: | 5'6" |
| Weight: | 190 lb |
| SBP: | 170 mmHg |
| DBP: | 112 mmHg |
| Serum creatinine: | 1.1 mg/dL |
| Patient name: | William |
| Age: | 55 |
| Height: | 5'10" |
| Weight: | 215 lb |
| SBP: | 170 mmHg |
| DBP: | 98 mmHg |
| Serum creatinine: | 1.3 mg/dL |
| Patient name: | Evelyn |
| Age: | 53 |
| Height: | 5'2" |
| Weight: | 168 lb |
| SBP: | 146 mmHg |
| DBP: | 94 mmHg |
| Serum creatinine: | 1.9 mg/dL |
| Proteinuria: (urinary albumin- creatinine ratio) | 1800 mg/g |
USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, COZAAR and HYZAAR should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
Before prescribing COZAAR and HYZAAR, please read the Prescribing Information and Patient Information.
Home | BP Efficacy | Outcomes | Resources | Patient Profiles | Coverage & Availability | Contact Us | Request More Information | Prescribing Information | Patient Information
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
COZAAR® (losartan potassium tablets) and HYZAAR® (losartan potassium-hydrochlorothiazide tablets) are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA.
20851323(3)-07/08-COZ
